Opus Genetics (IRD) Current Deferred Revenue (2019 - 2020)
Opus Genetics (IRD) posted quarterly Current Deferred Revenue of $650000.0 for Q3 2020, down 56.67% year-over-year from $1.5 million in Q4 2019, and little changed quarter-over-quarter from $650000.0 in Q2 2020.
Opus Genetics (IRD) Current Deferred Revenue (2019 - 2020) Analysis & Trends
Opus Genetics (IRD) has reported Current Deferred Revenue for 2 consecutive years, with $650000.0 the latest figure, recorded in Q3 2020.
- In Q3 2020, Current Deferred Revenue fell 56.67% year-over-year to $650000.0; the TTM figure through Sep 2020 stood at $650000.0 (down 56.67% YoY), while the FY2019 annual figure was $1.5 million, changed N/A from the prior year.
- Current Deferred Revenue steadied at $650000.0 in Q3 2020 per IRD's latest filing, from $650000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $1.5 million in Q2 2019 and bottomed at $150000.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 650,000.00 |
| Jun 30, 2020 | 650,000.00 |
| Mar 31, 2020 | 600,000.00 |
| Dec 31, 2019 | 1.50 Mn |
| Sep 30, 2019 | 1.50 Mn |
| Jun 30, 2019 | 1.50 Mn |
| Mar 31, 2019 | 150,000.00 |